This past week, Stimaire, Inc. had its second application (US Patent Pub. No. 20200338358) related to neurostimulation publish. The '358 application titled "Wireless Neural Stimulator with Injectable", teaches a device and method which utilizes sub-millimeter injectable stimulators used in conjunction with an external wearable magnetic field generator. The stimulators contain coils on the inside, and are small enough to fit within a 14-gauge needle. When the coils are exposed to a magnetic field, they produce small electrical voltage as explained by Faraday's Law. The '358 application utilizes these small electrical voltages for neurostimulation. The small size of the stimulators allow them to injected into the body without the complications of surgery, and since the electrical voltage is the result of an external magnetic field, there is no need for an interior power source. Once positioned in the body an applied magnetic field can be used to apply neurostimulation at varying intensities and durations as needed.
Stimaire's website boasts that its technology will be used to treat a whole range of disorders including pain disorders, mental disorders, sensory disorder, muscular disorders, and even sleep apnea. The small size of the stimulator, along with the lack of internal power source suggests that the device may have implications in long term treatment, or for use in individuals where surgical implementation of a neurostimulator would be too risky.
The '358 application follows the other existing patent for Stimaire, which issued this past August for a similar technology. While Stimaire may still be a newcomer to the neurostimulation game, the company's board of advisors includes a strong list of individuals with academic ties to UC Berkley, Cornell, UCLA, and Boston University, as well as connections with other medical startups like Tempronics Inc. and Setpoint Medical. Make sure to subscribe to the Magic Number® AI Biotech/Diagnostic Patent Forecast® to watch first-hand how medical startup's like Stimaire develop its patent portfolios.
